Neurocrine Biosciences To Present At Deutsche Bank's 2012 dbAccess BioFEST
Live Audio Webcast Tuesday, December 4, 2012
PR NewswirePress Release: Neurocrine Biosciences, Inc. – Tue, Nov 27, 2012 5:00 PM EST
SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 2012 dbAccess BioFEST in Boston.
The live presentation takes place on Tuesday, December 4 at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600 or ir@neurocrine.com. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
Live Audio Webcast Tuesday, December 4, 2012
PR NewswirePress Release: Neurocrine Biosciences, Inc. – Tue, Nov 27, 2012 5:00 PM EST
SAN DIEGO, Nov. 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at Deutsche Bank's 2012 dbAccess BioFEST in Boston.
The live presentation takes place on Tuesday, December 4 at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600 or ir@neurocrine.com. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, tardive dyskinesia, uterine fibroids, stress-related disorders, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.
Recent NBIX News
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 04/06/2026 09:08:18 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 04/06/2026 11:39:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 11:35:19 AM
- Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio • PR Newswire (US) • 04/06/2026 11:00:00 AM
- Neurocrine unveils first expert guidance for tardive dyskinesia care in long-term facilities • IH Market News • 03/26/2026 03:27:23 PM
- Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings • PR Newswire (US) • 03/26/2026 12:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:56:51 PM
- Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer • PR Newswire (US) • 03/17/2026 08:05:00 PM
- Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum • PR Newswire (US) • 03/10/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:18:36 PM
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in March • PR Newswire (US) • 02/24/2026 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 12:12:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:49:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:48:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:47:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:46:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:46:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:45:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:44:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:44:03 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 09:03:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:02:00 PM
- Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 • PR Newswire (US) • 02/11/2026 09:01:00 PM

